Johnson & Johnson

The biosimilar Ustekinumab-kfce is set for commercialisation in the US by February 2025 under a licensing agreement with Janssen

Patent dispute settlement with Janssen clears path for biosimilar to Stelara in key global markets

With the FDA’s approval, label restrictions that were included when the medicine was granted accelerated approval in the US in…

Phase 1 trial shows 90 per cent recurrence-free survival and 90 per cent complete response in patients with high-risk and…

ADCs continue to be the hot topic in big pharma. Prior to the announced J&J deal, last year alone saw 155 deals struck for the…

Akeega’s current predicted sales will experience only a slight increase as a result of its narrow label and fierce competition…

Market cap surged from $3.49 trillion during the first quarter (Q1) of 2023 to $3.56 trillion in Q2 2023

Both Johnson & Johnson and Pfizer criticised the changes by referencing the positive role of patents in incentivising their…

Dr Reed will join J&J on April 3, 2023, assuming responsibility for the company’s portfolio from Dr William Hait, who has…

J&J's teclistamab, branded as Tecvayli, is approved for treating adults with multiple myeloma that is hard to treat, or has…